NRAS, NRAS proto-oncogene, GTPase, 4893

N. diseases: 611; N. variants: 17
Disease: melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Whereas many studies have analyzed RAF and PI3K signaling in mutant NRAS melanoma, the role of RalGEF/Ral is understudied and TBK1 has not been examined. 24962318 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE When compared to WT, multivariate analysis of melanoma-specific survival (MSS) identified NRAS mutations as an adverse prognostic factor [hazard ratio (HR) 2.96; P = 0.04] but not BRAF(V600E) mutations (HR 1.73; P = 0.23). 21615881 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE When NRAS(G12D) was expressed in the melanocytes of developing embryos, it induced melanocyte proliferation and congenital melanocytic lesions reminiscent of human blue nevi but did not induce cutaneous melanoma. 23303902 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease LHGDN We suggest that co-overexpression of KIT/CDK4 is a potential mechanism of oncogenic transformation in some BRAF/NRAS wild-type melanomas. 18632627 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We sought to evaluate whether tumor genotype (e.g., NRAS mutations) correlates with benefit from immune therapy in melanoma. 25736262 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE We sought to determine for 1,227 participants in the international population-based Genes, Environment, and Melanoma (GEM) study whether MC1R and phenotypes were associated with melanoma BRAF/NRAS subtypes. 28842324 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We searched for point mutations in the N-ras gene in a large series of primary and metastatic MM from 81 different retrospectively selected patients using the very sensitive denaturing gradient gel electrophoresis technique, followed by sequencing. 11406571 2001
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We screened 85 melanoma samples for the most common B-RAF and N-RAS mutations found in melanoma using a site-directed mutagenesis-based detection technique. 14695143 2003
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We screened 115 melanoma samples for the most common B-RAF and N-RAS mutations found in melanoma using a site-directed mutagenesis-based detection technique. 15737846 2005
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We retrospectively analyzed 17 cases and focused on the histologic presentation and the expression of c-Kit, epidermal growth factor receptor (EGFR), cyclin D1/Bcl-1, PS100, and HMB45 and searched for BRAF, NRAS, and KIT mutations that are known to be associated with melanoma subtypes, together with amplifications of KIT, cyclin D1, cyclin-dependent kinase 4, MDM2, and microphthalmia-associated transcription factor using quantitative polymerase chain reaction. 23664541 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease BEFREE We now show that recently discovered NRAS isoform 2 is up-regulated in the setting of BRAF inhibitor resistance in melanoma, in both cell lines and patient tumor tissues. 28827320 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE We noted 197 regional amplifications, including some centered on the melanoma oncogenes MITF (n = 9), NRAS (n = 3), BRAF (n = 3), and CCND1 (n = 3). 17363583 2007
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease BEFREE We investigated the regulation of TERT expression in melanoma cell lines and our results show that promoter mutations render TERT expression dependent on MAPK activation due to oncogenic BRAF or NRAS mutations. 27449293 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We investigated the clinical and pathological associations of RAC1(P29S) in a cohort of 814 primary cutaneous melanomas with known BRAF and NRAS mutation status. 25043693 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We investigated the associations between BRAF(V600E) and NRAS(Q61R) mutations and known risk factors, clinicopathologic characteristics and clinical outcomes of melanoma in a case series of primary invasive cutaneous melanoma from the Nurses' Health Study (NHS). 25048604 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We have previously shown that mutations in the N-ras gene occur more frequently in melanomas originating from sun-exposed body sites, indicating that these mutations are UV induced. 10070891 1999
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We have investigated 37 sporadic malignant melanomas (15 primary cutaneous melanomas and 22 melanoma metastases) and 6 melanoma cell lines for mutations in the 3 Ras genes NRAS, KRAS and HRAS. 14961576 2004
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA. 20925915 2010
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We have not found significant correlation between mutational status (BRAF/NRAS) and OS; however, for BRAF or NRAS mutated melanomas we observed significantly shorter disease-free survival (DFS) when compared with wild-type melanoma patients (p = .04; 5-year DFS, 18 vs 19 vs 31 %, respectively). 24866436 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We further show that 2ME is effective against melanoma with different BRAF and NRAS mutational status. 28212889 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease BEFREE We found that the RICTOR locus is frequently amplified and overexpressed in melanoma and that RICTOR over-expression in NRAS-transformed melanocytes stimulates their clonogenicity, demonstrating that RICTOR amplification can cooperate with NRAS mutation to stimulate melanoma proliferation. 26356562 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We found that a subset of BRAF- and NRAS-mutant human melanomas resistant to the MEK inhibitor selumetinib displayed increased oxidative phosphorylation (OxPhos) mediated by the transcriptional coactivator PGC1α. 25297634 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We found few significantly somatically mutated genes (~6 per spontaneous and 15 per UVR-induced melanoma) in addition to the Cdk4 and NRAS mutations already present. 26477315 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We do not observe this pathway in NRAS mutant melanoma or BRAF mutant colorectal cells. 21215707 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE We defined and assessed a panel of histomorphologic measures and correlated them with the mutation status of the oncogenes BRAF and NRAS in a cohort of 302 archival tissues of primary cutaneous melanomas from an academic comprehensive cancer center. 18532874 2008